<DOC>
	<DOCNO>NCT01330199</DOCNO>
	<brief_summary>The purpose study develop predictive antiretroviral pharmacokinetic model mucosal fluid tissue distribution genital tract fluid , rectal fluid 3 mucosal tissue . This accomplish determine pharmacokinetic disposition dose proportionality four antiretrovirals ( tenofovir , emtricitabine , maraviroc , raltegravir ) human rectal cervicovaginal fluid rectal , cervical , vaginal tissue .</brief_summary>
	<brief_title>Pharmacokinetics Tenofovir , Emtricitabine , Maraviroc , Raltegravir Cervical , Vaginal , Rectal Tissues Secretions</brief_title>
	<detailed_description />
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Healthy premenopausal female subject age 18 49 year , inclusive , intact gastrointestinal tract , uterus , cervix . ( Healthy define irregular menstrual cycle clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test . ) All subject must estimate calculated creatinine clearance least 80 mL/min CockcroftGault formula All subject must negative serum pregnancy test screen negative urine pregnancy test day sample use least one follow method contraception : Systemic hormonal contraceptive ( oral , depot , transdermal implant ) IUD place least 1 month prior study enrollment Bilateral tubal ligation ( Sterilization ) Vasectomized male partner Condom + Spermicide *Unless engage sexual activity female sex partner abstinent least 3 month prior intention become sexually active study period . Any history recent present concomitant male sex partner address ruled context screen participant eligibility protocol Female partner Body Mass Index ( BMI ) approximately 18 34 kg/m^2 ; total body weight &gt; 45 kg ( 99 lb ) . Evidence personally sign date informed consent document indicate subject inform pertinent aspects trial . Willing able comply schedule visit , treatment plan , laboratory test , trial procedure . Subject must normal pap smear within 36 month screen visit , procedures abnormal cervical/vaginal pathology last six month , least one prior gynecological visit part subject 's routine medical history . Subject must willing abstain sexual intercourse , douche , intravaginal intrarectal product least 72 hour prior Day 1 study completion . Subject must HIV1 Hepatitis B surface antigen negative document screen lab . Subject must actively involved conception process . Subject must able swallow pill allergies component study product . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include document drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Subjects history hysterectomy Subjects pregnant , possibly pregnant , lactating Subjects presence vaginal discharge genital bleed screen History febrile illness within five day prior first dose . Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug screen . A positive result HIV . Active Hepatitis B infection determine positive Hepatitis B surface antigen ( HbsAg ) Hepatitis B core antibody ( HBcAb ) test ( absence HBsAb ) . Active Hepatitis C infection define antihepatitis C virus serology ( determine multiantigen EIA ) detectable Hepatitis C viral RNA . A positive test syphilis , gonorrhea , Chlamydia , trichomonas screen symptomatic bacterial vaginosis . Any laboratory chemistry hematology result Grade 2 great accord DAIDS Laboratory Grading Tables . Treatment investigational drug within 4 month precede first dose trial medication . History regular alcohol consumption exceed 14 drink ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) spirit ) per week . Participation clinical trial involve vaginal rectal biopsy within 12 month precede first dose trial medication . Use prescription nonprescription drug , vitamin , dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose trial medication . As exception , systemic hormonal method contraception continue . Blood donation approximately 1 pint ( 500 mL ) within 56 day prior dose History sensitivity heparin heparininduced thrombocytopenia Any vaccination within 30 day study entry Allergy lidocaine Mohl 's solution Allergy latex Abnormal pap smear past 12 month Any degree ectopy abnormality evident pelvic exam screen Any condition , opinion investigator , likely interfere followup ability take study medication appropriately . Unwilling unable comply follow dietary restriction regard study drug administration : Subjects must abstain food drink ( except water ) least 4 hour prior safety laboratory evaluation Subjects must abstain food drink ( except water ) last 8 hour prior start pharmacokinetic sample collection Subjects allow eat drink grapefruit contain product 7 day prior first dose trial medication collection final pharmacokinetic blood sample . While confine , total daily nutritional composition approximately 50 % carbohydrate , 35 % fat 15 % protein , daily caloric intake per subject exceed approximately 3200 kcal . Subjects require consume clear liquid diet night rectal biopsy procedure procedure complete</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Female</keyword>
	<keyword>Volunteer</keyword>
</DOC>